Literature DB >> 17119978

Outcome of children with posterior fossa medulloblastoma: a single institution experience over the decade 1994-2003.

D Kombogiorgas1, S Sgouros, A R Walsh, A D Hockley, M Stevens, R Grundy, A Peet, M English, D Spooner.   

Abstract

AIM: While the impact of radiotherapy in the management of medulloblastoma was recognised, the introduction of chemotherapy was investigated in clinical trials and shown to confer an additional advantage. We reviewed the outcome of a series of consecutive patients to assess the impact in a population-based clinical establishment.
MATERIALS AND METHODS: A series of 38 children treated for medulloblastoma at Birmingham Children's Hospital between 1994 and 2003 was analysed. The effect of surgery, radiotherapy, chemotherapy and metastasis on survival was analysed.
RESULTS: The overall 5-year survival rate was 61.4% for the 36 patients who had resective surgery, while 2 patients had biopsy only and died within a few months. There was no operative mortality. The incidence of hydrocephalus needing permanent shunting was higher in the first 3 years of life (p = 0.007, chi-square). The 5-year survival rate of patients with total and sub-total excision of medulloblastoma was 61.1% and 61.8%, respectively. The 5-year survival rate of patients older than 3 years was 73.4% and for patients under 3 years was 36.3% (p = 0.007, log rank). Metastases at presentation did not influence survival. All deaths occurred in the first 32 months.
CONCLUSION: The contribution of chemotherapy in the improvement of the overall survival appears more evident in children younger than 3 years or presenting with metastases. The absence of significant difference in survival between patients with total or sub-total excision of medulloblastoma supports the view that total excision of medulloblastoma can be avoided when the risk for potential intra-operative damage and consequent neurological deficits is high.

Entities:  

Mesh:

Year:  2006        PMID: 17119978     DOI: 10.1007/s00381-006-0258-5

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  40 in total

1.  Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I).

Authors:  D M Tait; H Thornton-Jones; H J Bloom; J Lemerle; P Morris-Jones
Journal:  Eur J Cancer       Date:  1990-04       Impact factor: 9.162

2.  The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone.

Authors:  A E Evans; R D Jenkin; R Sposto; J A Ortega; C B Wilson; W Wara; I J Ertel; S Kramer; C H Chang; S L Leikin
Journal:  J Neurosurg       Date:  1990-04       Impact factor: 5.115

3.  Influence of a child's sex on medulloblastoma outcome.

Authors:  M D Weil; K Lamborn; M S Edwards; W M Wara
Journal:  JAMA       Date:  1998-05-13       Impact factor: 56.272

4.  Medulloblastoma: a population-based study of 532 cases.

Authors:  R O Roberts; C F Lynch; M P Jones; M N Hart
Journal:  J Neuropathol Exp Neurol       Date:  1991-03       Impact factor: 3.685

5.  Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children.

Authors:  Jacques Grill; Christian Sainte-Rose; Anne Jouvet; Jean-Claude Gentet; Odile Lejars; Didier Frappaz; François Doz; Xavier Rialland; Fabienne Pichon; Anne-Isabelle Bertozzi; Pascal Chastagner; Dominique Couanet; Jean-Louis Habrand; Marie-Anne Raquin; Marie-Cécile Le Deley; Chantal Kalifa
Journal:  Lancet Oncol       Date:  2005-08       Impact factor: 41.316

6.  Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study.

Authors:  P M Zeltzer; J M Boyett; J L Finlay; A L Albright; L B Rorke; J M Milstein; J C Allen; K R Stevens; P Stanley; H Li; J H Wisoff; J R Geyer; P McGuire-Cullen; J A Stehbens; S B Shurin; R J Packer
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

Review 7.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

Review 8.  Short- and long-term complications of radiation therapy for pediatric brain tumors.

Authors:  B Donahue
Journal:  Pediatr Neurosurg       Date:  1992       Impact factor: 1.162

Review 9.  Prognostic factors in medulloblastoma.

Authors:  M T Giordana; P Schiffer; D Schiffer
Journal:  Childs Nerv Syst       Date:  1998-06       Impact factor: 1.475

10.  Combined therapy of medulloblastoma: review of 46 patients treated in a single institution.

Authors:  G Calaminus; G Janssen; H G Lenard; W J Bock; G Reifenberger; G Schmitt; U Göbel
Journal:  Neuropediatrics       Date:  1998-04       Impact factor: 1.947

View more
  11 in total

Review 1.  Use of T2 signal intensity of cerebellar neoplasms in pediatric patients to guide preoperative staging of the neuraxis.

Authors:  Jonathan A Forbes; Lola B Chambless; Jason G Smith; Curtis A Wushensky; Richard L Lebow; JoAnn Alvarez; Matthew M Pearson
Journal:  J Neurosurg Pediatr       Date:  2011-02       Impact factor: 2.375

2.  Appraisal of the current staging system for residual medulloblastoma by volumetric analysis.

Authors:  Dimitris Kombogiorgas; Stephanie Puget; Nathalie Boddaert; Andrew Peet; Martin English; Kal Natarajan; Jacques Grill; Dominique Couanet; Christian Sainte-Rose; Spyros Sgouros
Journal:  Childs Nerv Syst       Date:  2011-08-04       Impact factor: 1.475

3.  The clinical experience of medulloblastoma treatment and the significance of time sequence for development of leptomeningeal metastasis.

Authors:  Po-Chuan Hsieh; Chieh-Tsai Wu; Kuang-Lin Lin; Tang-Her Jaing; Chen-Kan Tseng; Tai-Ngar Lui; Shih-Ming Jung
Journal:  Childs Nerv Syst       Date:  2008-09-19       Impact factor: 1.475

4.  SPARC expression induces cell cycle arrest via STAT3 signaling pathway in medulloblastoma cells.

Authors:  Chandramu Chetty; Ranadheer Dontula; Purnachandra Nagaraju Ganji; Meena Gujrati; Sajani S Lakka
Journal:  Biochem Biophys Res Commun       Date:  2011-12-20       Impact factor: 3.575

Review 5.  Anti-cancer role of SPARC, an inhibitor of adipogenesis.

Authors:  Ganji Purna Chandra Nagaraju; Dipali Sharma
Journal:  Cancer Treat Rev       Date:  2011-01-14       Impact factor: 12.111

6.  Surgical outcome of children with medulloblastoma: a retrospective study of a 405-patient series from Children's Cancer Hospital Egypt (CCHE-57357).

Authors:  Abd Elrhman Enayet; Mohamed Nabil; Mohamed Reda Rady; Yasser Yousef; Eman Badawy; Mohamed A El Beltagy
Journal:  Childs Nerv Syst       Date:  2021-02-18       Impact factor: 1.475

7.  siRNA-mediated downregulation of MMP-9 and uPAR in combination with radiation induces G2/M cell-cycle arrest in Medulloblastoma.

Authors:  Ganji Purna Chandra Nagaraju; Arun Kumar Nalla; Reshu Gupta; Sanjeeva Mohanam; Meena Gujrati; Dzung H Dinh; Jasti S Rao
Journal:  Mol Cancer Res       Date:  2010-12-10       Impact factor: 5.852

8.  Cancer-testis (CT) antigen expression in medulloblastoma.

Authors:  Sueli M Oba-Shinjo; Otavia L Caballero; Achim A Jungbluth; Sergio Rosemberg; Lloyd J Old; Andrew J G Simpson; Suely K N Marie
Journal:  Cancer Immun       Date:  2008-04-22

9.  Medulloblastoma in childhood-King Edward Memorial hospital surgical experience and review: Comparative analysis of the case series of 365 patients.

Authors:  Dattatraya Muzumdar; Amit Deshpande; Ratnesh Kumar; Ankur Sharma; Naina Goel; Nitin Dange; Abhida Shah; Atul Goel
Journal:  J Pediatr Neurosci       Date:  2011-10

10.  MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma.

Authors:  Livia Garzia; Immacolata Andolfo; Emilio Cusanelli; Natascia Marino; Giuseppe Petrosino; Daniela De Martino; Veronica Esposito; Aldo Galeone; Luigi Navas; Silvia Esposito; Sara Gargiulo; Sarah Fattet; Vittoria Donofrio; Giuseppe Cinalli; Arturo Brunetti; Luigi Del Vecchio; Paul A Northcott; Olivier Delattre; Michael D Taylor; Achille Iolascon; Massimo Zollo
Journal:  PLoS One       Date:  2009-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.